Attached files
| file | filename |
|---|---|
| EX-99.1 - China Shenghuo Pharmaceutical Holdings Inc | v204952_ex99-1.htm |
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): December 8, 2010
CHINA
SHENGHUO PHARMACEUTICAL HOLDINGS, INC.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
001-33537
|
20-2903562
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
No.
2, Jing You Road
|
|
|
Kunming
National Economy &
|
|
|
Technology
Developing District
|
|
|
People’s
Republic of China 650217
|
N/A
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
0086-871-728-2628
(Registrant’s
Telephone Number, Including Area Code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01. Other
Events.
On
December 8, 2010, China Shenghuo Pharmaceutical Holdings, Inc. (the “Company”)
issued a press release announcing that the NYSE Amex LLC (the “Exchange”) had
accepted the Company’s plan of compliance for continued listing. The
Exchange granted a listing extension until March 22, 2012, during which time the
Company will be subject to periodic review by Exchange staff.
A copy of
the Company’s press release is attached to this Current Report on Form 8-K as
Exhibit 99.1 and the information therein is incorporated herein by
reference.
Item
9.01. Financial
Statements and Exhibits.
|
(d)
|
Exhibits
|
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release of China Shenghuo Pharmaceutical Holdings, Inc., dated December 8,
2010
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
CHINA
SHENGHUO PHARMACEUTICAL HOLDINGS, INC.
|
|||
|
Date:
December 8, 2010
|
|||
|
By:
|
/s/
Gui Hua Lan
|
||
|
Name:
Gui Hua Lan
Title:
Chief Executive Officer
|
|||
3
EXHIBIT
INDEX
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release of China Shenghuo Pharmaceutical Holdings, Inc., dated December 8,
2010
|
4